Marco Testori

Immunology and Microbiology · Life Sciences

4h-index103citations26works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(11), Cancer Immunotherapy and Biomarkers(9), Ovarian cancer diagnosis and treatment(8), Ferroptosis and cancer prognosis(7), Virus-based gene therapy research(3)

Publications26 total

Supplementary Figure 2 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 3 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 4 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Data from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 1 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Figure 2 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Table 1 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Figure 3 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Supplementary Table 2 from Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
2026Open Access
Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
Cancer Research Communications·2025Open Access
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring
Frontiers in Immunology·2024· 7 citedOpen Access
1505 Spatial profiling of the SCLC tumor microenvironment defined by high MHC-I expression reveals association with functionally relevant antigen presentation
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
155 MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells
Regular and Young Investigator Award Abstracts·2022· 1 citedOpen Access
Abstract 1711: A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in non-small cell lung cancer
Cancer Research·2022
39 A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC
Regular and Young Investigator Award Abstracts·2021Open Access
FP07.02 Deep Learning Based Analysis of Multiplex IHC Accurately Interprets PD-L1 and Provides Prognostic Information in NSCLC
Journal of Thoracic Oncology·2021Open Access
P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies
2020· 1 citedOpen Access
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
Nature Communications·2019· 43 citedOpen Access
Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Annals of Oncology·2019· 2 citedOpen Access
Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
Frontiers in Immunology·2018· 28 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Michael Surace(15), Miljenka Vuko(14), Helen K. Angell(10), Barrett Nuttall(10), Andrea Ennio Storti(10), Shaan Gill(10), Emma V. Jones(9), Andreas Spitzmüller(9), James Boyle(9), Jan Maciej Zaucha(9), Monica Azqueta-Gavaldon(9), Amelia Raymond(9), Katrina Moore(9), Paola Marco-Casanova(9), Ben Sidders(9), Nadeem Riaz(9), Maurizio Scaltriti(9), Anita Semertzidou(9), Felicia Ng(7), Marlene Geiger(6)